Browse the corpus

Baricitinib is a disease-modifying antirheumatic drug (DMARD) indicated for rheumatoid arthritis when conventional DMARDs prove inadequate. This medication is approved by the U.S. Food and Drug Administration (FDA) to treat adult patients with moderately to severely active rheumatoid arthritis who have not responded adequately to other DMARDs, including tumor necrosis factor antagonist therapies. Furthermore, baricitinib is FDA-approved for treating COVID-19, presenting a valuable choice in combination with other therapies for hospitalized patients, including pediatric cases necessitating supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. This activity comprehensively reviews the indications, contraindications, mechanisms, adverse events, and other crucial aspects of baricitinib therapy within the clinical setting. This activity is tailored to meet the specific needs of an interprofessional healthcare team responsible for treating patients with rheumatoid arthritis, alopecia areata, and COVID-19. Objectives: Identify the appropriate patient population for baricitinib therapy, recognizing those with moderate-to-severe active rheumatoid arthritis who have not responded adequately to other disease-modifying antirheumatic drugs. Differentiate between the indications for baricitinib in rheumatoid arthritis and its FDA-approved use in the treatment of COVID-19. Assess patients regularly for potential adverse effects, specifically on laboratory monitoring, including liver function tests, lipid panels, and complete blood counts. Collaborate with an interprofessional healthcare team, including specialists, pharmacists, and nurses, to improve treatment outcomes and ensure comprehensive and coordinated care for patients on baricitinib. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose In clinical trials, both single doses of baricitinib of up to 40 mg and multiple doses of baricitinib of up to 20 mg for 10 days were assessed, and no dose-limiting toxicity was observed. Adverse events were comparable to those of lower doses, including nausea, vomiting, recurrent infections, hypersensitivity reactions, and myelosuppression. Management of Overdose In the event of an overdose, patients should be closely monitored for signs and symptoms of adverse reactions and promptly seek medical attention.[30] As there is no antidote for baricitinib, patients should be provided with supportive care.

For optimal patient outcomes, open communication among the interprofessional healthcare team and patients is essential, particularly in closely monitoring for the development of adverse reactions. Patients should undergo thorough screening for viral hepatitis and tuberculosis before initiating the drug. In addition, patients should be advised to promptly inform their clinicians of any signs and symptoms related to infection, particularly if they travel to areas with an increased prevalence of tuberculosis. Clinicians must ensure that patients are up-to-date on immunizations before initiating the drug. Baseline CBC with differential, LFTs, and RFTs should be obtained before initiating the drug, and regular monitoring should be maintained for potential dosage adjustments. The lipid panel should be monitored after the initiation of the drug. Patients should be encouraged to attend regular follow-up visits. Clinicians should be vigilant for any signs of active infection during every visit. In the event of a severe illness, including the reactivation of herpes zoster, discontinuation of the drug is recommended. For patients with a history of DVT or pulmonary embolism, the use of baricitinib should be approached cautiously. Patients should be educated about the signs and symptoms of blood clot development and advised to seek immediate medical attention if such symptoms arise. Clinicians should exercise caution when using baricitinib in patients with a history of diverticulitis. They should maintain a lower threshold to rule out gastrointestinal perforation in cases of abdominal pain and advise patients to seek emergent medical attention if such symptoms occur. Clinicians should refrain from prescribing baricitinib to pregnant patients and educate them on effective contraception before initiating the drug. In the event of pregnancy, patients should promptly contact their healthcare providers. Patients should be educated on the potential adverse effects, including the development of skin cancers and lymphoma.

Clinicians should refrain from prescribing baricitinib to pregnant patients and educate them on effective contraception before initiating the drug. In the event of pregnancy, patients should promptly contact their healthcare providers. Patients should be educated on the potential adverse effects, including the development of skin cancers and lymphoma. In summary, baricitinib is a relatively new addition to the DMARDs within the JAK inhibitors family, showing promising results. Achieving effective outcomes requires collaborative efforts among patients and an interprofessional healthcare team, including clinicians, nursing staff, pharmacists, and specialists. Nursing staff are crucial in monitoring patients' drug compliance and screening for potential adverse effects in collaboration with coordinating clinicians. Pharmacists can contribute by ensuring appropriate drug dosing, considering the patient's comorbidities, and providing valuable feedback regarding potential drug interactions. Other specialists, such as infectious disease specialists, hematologists, and gastroenterologists, can be consulted if the patient develops potential adverse effects. Vigilance toward any signs and symptoms of toxicity is crucial for improving outcomes and reducing morbidity. An interprofessional team approach, along with open communication among clinicians (MDs, DOs, NPs, and PAs), specialists, pharmacists, and nurses, is essential to enhance patient outcomes while minimizing adverse effects.